Cellebrite DI (CLBT) Operating Expenses (2020 - 2026)

Cellebrite DI has reported Operating Expenses for 7 years, with the latest figure at $99.0 million in Q2 2026.

• On a quarterly basis, Operating Expenses rose 21.93% year-over-year to $99.0 million in Q2 2026; TTM through Jun 2026 was $370.8 million, a 20.92% increase from a year earlier, with the FY2025 full-year figure at $334.0 million, up 18.57% from the prior year.
• Operating Expenses was $99.0 million for Q2 2026 at Cellebrite DI, up from $96.8 million in the prior quarter.
• The five-year high for Operating Expenses was $99.0 million in Q2 2026, with the low at $52.2 million in Q4 2022.
• Average Operating Expenses over 5 years is $70.5 million, with a median of $67.0 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses jumped 34.72% in 2022, then declined 0.69% in 2023.
• Over 5 years, Operating Expenses stood at $52.2 million in 2022, then climbed by 20.85% to $63.1 million in 2023, then climbed by 19.97% to $75.7 million in 2024, then advanced by 16.68% to $88.3 million in 2025, then advanced by 12.07% to $99.0 million in 2026.
• The last three Operating Expenses figures came in at $99.0 million (Q2 2026), $96.8 million (Q1 2026), and $88.3 million (Q4 2025), per Business Quant data.